<DOC>
	<DOCNO>NCT00503503</DOCNO>
	<brief_summary>The objective surveillance determine follow item patient receive Enbrel certain period marketing : 1 ) unlabeled adverse event , 2 ) onset ( frequency , severity detail ) adverse event , 3 ) factor consider affect safety , 4 ) efficacy Enbrel . Moreover , onset ( frequency , severity detail ) following key issue surveillance : Infection ( tuberculosis , opportunistic infection , etc . ) , autoimmune disease , cardiac failure , malignant tumor , interstitial pneumonia , demyelinate disorder , pancytopenia , aplastic anemia application site reaction .</brief_summary>
	<brief_title>Study Evaluating Efficacy Enbrel ( Etanercept ) Subjects Japan</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Inclusion Criteria Â· Patients rheumatoid arthritis [ refractory previous treatment ]</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>